Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790 · SHASTA-10 Phase 3Active, not recruiting
- Lead sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrollment
- 710 (actual)
- Start date
- 9 Apr 2025
- Primary completion
- Jul 2028 (estimated)
- Study completion
- 1 Jul 2028
- Last update posted
- 1 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Plozasiran Injection Drug
Conditions and primary outcome
- Hypertriglyceridemia
Primary outcome
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (From first dose of study drug through Month 24)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06822790.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06822790 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.